SMITH & NEPHEW PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,001 GBX | -0.99% |
|
-3.66% | -7.28% |
Financials (USD)
| Sales 2024 * | 5.81B | Sales 2025 * | 6.12B | Capitalization | 11.25B |
|---|---|---|---|---|---|
| Net income 2024 * | 527M | Net income 2025 * | 691M | EV / Sales 2024 * | 2.38 x |
| Net Debt 2024 * | 2.61B | Net Debt 2025 * | 2.3B | EV / Sales 2025 * | 2.21 x |
| P/E ratio 2024 * |
22.7
x | P/E ratio 2025 * |
16.8
x | Employees | 18,452 |
| Yield 2024 * |
2.93% | Yield 2025 * |
3.3% | Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Smith & Nephew Plc
More press releases
More news
| 1 day | -0.94% | ||
| 1 week | -3.66% | ||
| Current month | +0.97% | ||
| 1 month | -1.77% | ||
| 3 months | -7.71% | ||
| 6 months | -7.58% | ||
| Current year | -7.28% |
1 week
996.07
1 038.00
1 month
967.801 046.50
Current year
946.001 181.50
1 year
887.001 269.00
3 years
887.001 601.50
5 years
887.002 023.00
10 years
881.002 023.00
| Managers | Title | Age | Since |
|---|---|---|---|
Deepak Nath
CEO | Chief Executive Officer | - | 22-03-31 |
John Rogers
DFI | Director of Finance/CFO | 56 | Nov. 30 |
Alison Parkes
CMP | Compliance Officer | - | 99-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marc E. Owen
BRD | Director/Board Member | 65 | 17-09-30 |
Jeremy Maiden
BRD | Director/Board Member | 62 | 23-09-13 |
Rupert Soames
CHM | Chairman | 63 | 23-04-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.16% | 15 M€ | -2.91% | ||
| 0.52% | 11 M€ | +0.83% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 1,001 | -1.03% | 128 527 |
| 24-06-13 | 1,011 | -0.44% | 1,853,498 |
| 24-06-12 | 1,015 | +0.69% | 2,762,673 |
| 24-06-11 | 1,009 | -1.80% | 2,076,558 |
| 24-06-10 | 1,027 | -1.06% | 1,638,266 |
Delayed Quote London S.E., June 14, 2024 at 07:24 am EDT
More quotes
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows:
- orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders);
- sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.;
- wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc.
The United States accounts for 53.7% of net sales.
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.9
USD
Average target price
16.45
USD
Spread / Average Target
+27.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.28% | 11.25B | |
| +14.55% | 131B | |
| -10.14% | 7.84B | |
| +42.95% | 5.72B | |
| -17.77% | 4.97B | |
| +8.21% | 3.44B | |
| -19.83% | 2.46B | |
| -13.82% | 2.02B | |
| -15.84% | 1.87B | |
| -31.39% | 1.59B |
- Stock Market
- Equities
- SN. Stock
